Glenmark Life Sciences Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1084.60 +0.60 (0.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1061.25
Today’s High
1094.2
52 Week Low
620.05
52 Week High
1335
1080.05 -2.85 (-0.26%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1070.2
Today’s High
1095.85
52 Week Low
620.2
52 Week High
1335.1
Key Metrics
- Market Cap (In Cr) 13269.08
- Beta -
- Div. Yield (%) 2.08
- P/B 5.69
- TTM P/E 30.6
- Peg Ratio 3.09
- Sector P/E 31.15
- D/E 0.01
- Open Price 1061.25
- Prev Close 1084
Glenmark Life Sciences Analysis
Price Analysis
-
1 Week-0.74%
-
3 Months8.74%
-
6 Month32.04%
-
YTD64.81%
-
1 Year73.1%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 2
- 3
- Buy
- 2
- 2
- 2
- 1
- Hold
- 1
- 1
- 1
- 1
- Sell
- 0
- 0
- 1
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 6
- 6
- 6
- 5
Glenmark Life Sciences News
Stocks to watch: Mankind, TechM, IndiGo, Adani Green, DLF, Ashok Leyland
9 min read . 26 Jul 2024Glenmark Pharma to offload 7.84% stake in Glenmark Life Science through OFS
1 min read . 10 Jul 2024Glenmark Life Sciences Q4 Results Live : profit falls by 33.08% YOY
1 min read . 28 Apr 2024Glenmark Life Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2283.21
- Selling/ General/ Admin Expenses Total
- 258.16
- Depreciation/ Amortization
- 53.45
- Other Operating Expenses Total
- 348.8
- Total Operating Expense
- 1662.42
- Operating Income
- 620.79
- Net Income Before Taxes
- 631.29
- Net Income
- 470.89
- Diluted Normalized EPS
- 38.38
- Period
- 2024
- Total Assets
- 2850.41
- Total Liabilities
- 518.09
- Total Equity
- 2332.32
- Tangible Book Valueper Share Common Eq
- 189.14
- Period
- 2024
- Cashfrom Operating Activities
- 413.52
- Cashfrom Investing Activities
- -116.48
- Cashfrom Financing Activities
- -279.44
- Net Changein Cash
- 17.59
- Period
- 2023
- Total Revenue
- 2161.22
- Selling/ General/ Admin Expenses Total
- 474.99
- Depreciation/ Amortization
- 42.09
- Other Operating Expenses Total
- 25.4
- Total Operating Expense
- 1560.3
- Operating Income
- 600.92
- Net Income Before Taxes
- 628.61
- Net Income
- 466.96
- Diluted Normalized EPS
- 38.37
- Period
- 2023
- Total Assets
- 2702.15
- Total Liabilities
- 563.94
- Total Equity
- 2138.21
- Tangible Book Valueper Share Common Eq
- 173.04
- Period
- 2023
- Cashfrom Operating Activities
- 313.4
- Cashfrom Investing Activities
- -154.14
- Cashfrom Financing Activities
- -387.59
- Net Changein Cash
- -228.33
- Period
- 2022
- Total Revenue
- 2123.21
- Selling/ General/ Admin Expenses Total
- 463.52
- Depreciation/ Amortization
- 37.88
- Other Operating Expenses Total
- -0.32
- Total Operating Expense
- 1543.97
- Operating Income
- 579.24
- Net Income Before Taxes
- 564.92
- Net Income
- 418.72
- Diluted Normalized EPS
- 35.67
- Period
- 2022
- Total Assets
- 2471.01
- Total Liabilities
- 416.7
- Total Equity
- 2054.31
- Tangible Book Valueper Share Common Eq
- 166.81
- Period
- 2022
- Cashfrom Operating Activities
- 597.58
- Cashfrom Investing Activities
- -122.23
- Cashfrom Financing Activities
- -78.8
- Net Changein Cash
- 396.56
- Period
- 2021
- Total Revenue
- 1885.17
- Selling/ General/ Admin Expenses Total
- 384.55
- Depreciation/ Amortization
- 33.39
- Other Operating Expenses Total
- -0.38
- Total Operating Expense
- 1323.06
- Operating Income
- 562.1
- Net Income Before Taxes
- 470.94
- Net Income
- 351.58
- Diluted Normalized EPS
- 28.73
- Period
- 2021
- Total Assets
- 1997.08
- Total Liabilities
- 1244.33
- Total Equity
- 752.75
- Tangible Book Valueper Share Common Eq
- 60.79
- Period
- 2021
- Cashfrom Operating Activities
- 388.11
- Cashfrom Investing Activities
- -68.73
- Cashfrom Financing Activities
- -213.78
- Net Changein Cash
- 105.6
- Period
- 2020
- Total Revenue
- 1537.31
- Selling/ General/ Admin Expenses Total
- 373.66
- Depreciation/ Amortization
- 29.37
- Other Operating Expenses Total
- -0.4
- Total Operating Expense
- 1093.1
- Operating Income
- 444.22
- Net Income Before Taxes
- 421.07
- Net Income
- 313.1
- Diluted Normalized EPS
- 25.63
- Period
- 2020
- Total Assets
- 1725.6
- Total Liabilities
- 1323.91
- Total Equity
- 401.69
- Tangible Book Valueper Share Common Eq
- 32.2
- Period
- 2020
- Cashfrom Operating Activities
- 195.01
- Cashfrom Investing Activities
- -50.52
- Cashfrom Financing Activities
- -136.55
- Net Changein Cash
- 7.94
- Period
- 2019
- Total Revenue
- 886.42
- Selling/ General/ Admin Expenses Total
- 279.06
- Depreciation/ Amortization
- 6.95
- Other Operating Expenses Total
- 12.28
- Total Operating Expense
- 650.58
- Operating Income
- 235.84
- Net Income Before Taxes
- 228.3
- Net Income
- 195.59
- Diluted Normalized EPS
- 16.01
- Period
- 2019
- Total Assets
- 1475.4
- Total Liabilities
- 1387.27
- Total Equity
- 88.12
- Tangible Book Valueper Share Common Eq
- 6.67
- Period
- 2019
- Cashfrom Operating Activities
- 10.43
- Cashfrom Investing Activities
- -8.91
- Cashfrom Financing Activities
- 0.53
- Net Changein Cash
- 2.05
- Period
- 2024-09-30
- Total Revenue
- 506.88
- Selling/ General/ Admin Expenses Total
- 62.44
- Depreciation/ Amortization
- 15.09
- Other Operating Expenses Total
- 84.88
- Total Operating Expense
- 387.61
- Operating Income
- 119.27
- Net Income Before Taxes
- 127.46
- Net Income
- 95.32
- Diluted Normalized EPS
- 7.75
- Period
- 2024-09-30
- Total Assets
- 3084.86
- Total Liabilities
- 546.38
- Total Equity
- 2538.48
- Tangible Book Valueper Share Common Eq
- 205.76
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 219.58
- Cashfrom Investing Activities
- -73.11
- Cashfrom Financing Activities
- -1.77
- Net Changein Cash
- 144.7
- Period
- 2024-06-30
- Total Revenue
- 588.62
- Selling/ General/ Admin Expenses Total
- 56.84
- Depreciation/ Amortization
- 14.39
- Other Operating Expenses Total
- 84.5
- Total Operating Expense
- 443.52
- Operating Income
- 145.1
- Net Income Before Taxes
- 150.24
- Net Income
- 111.48
- Diluted Normalized EPS
- 9.08
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 536.6
- Selling/ General/ Admin Expenses Total
- 72.26
- Depreciation/ Amortization
- 14.53
- Other Operating Expenses Total
- 84.2
- Total Operating Expense
- 409.69
- Operating Income
- 126.91
- Net Income Before Taxes
- 129.68
- Net Income
- 97.94
- Diluted Normalized EPS
- 7.97
- Period
- 2024-03-31
- Total Assets
- 2850.41
- Total Liabilities
- 518.09
- Total Equity
- 2332.32
- Tangible Book Valueper Share Common Eq
- 189.14
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 413.52
- Cashfrom Investing Activities
- -116.48
- Cashfrom Financing Activities
- -279.44
- Net Changein Cash
- 17.59
- Period
- 2023-12-31
- Total Revenue
- 572.8
- Selling/ General/ Admin Expenses Total
- 71.05
- Depreciation/ Amortization
- 13.18
- Other Operating Expenses Total
- 87
- Total Operating Expense
- 413.42
- Operating Income
- 159.38
- Net Income Before Taxes
- 160.68
- Net Income
- 118.77
- Diluted Normalized EPS
- 9.67
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 595.36
- Selling/ General/ Admin Expenses Total
- 66.71
- Depreciation/ Amortization
- 13.13
- Other Operating Expenses Total
- 88.48
- Total Operating Expense
- 441.41
- Operating Income
- 153.95
- Net Income Before Taxes
- 158.92
- Net Income
- 118.74
- Diluted Normalized EPS
- 9.69
- Period
- 2023-09-30
- Total Assets
- 2952.98
- Total Liabilities
- 561.24
- Total Equity
- 2391.74
- Tangible Book Valueper Share Common Eq
- 193.79
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 216.22
- Cashfrom Investing Activities
- -55.23
- Cashfrom Financing Activities
- -1.87
- Net Changein Cash
- 159.12
- Period
- 2023-06-30
- Total Revenue
- 578.45
- Selling/ General/ Admin Expenses Total
- 48.13
- Depreciation/ Amortization
- 12.61
- Other Operating Expenses Total
- 89.12
- Total Operating Expense
- 397.9
- Operating Income
- 180.55
- Net Income Before Taxes
- 182
- Net Income
- 135.45
- Diluted Normalized EPS
- 11.05
- Period
- 2023-06-30
- Period
- 2023-06-30
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Glenmark Life Sciences Technical
Moving Average
SMA
- 5 Day1082.05
- 10 Day1084.88
- 20 Day1059.23
- 50 Day1126.75
- 100 Day1024.62
- 300 Day995.85
Glenmark Life Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Marksans Pharma
- 309
- 3.15
- 1.03
- 328.35
- 126.05
- 14002.76
- Granules India
- 545.3
- -6.3
- -1.14
- 724.55
- 359.85
- 13216.37
- Glenmark Life Sciences
- 1084.6
- 0.6
- 0.06
- 1335
- 620.05
- 13289.3
- Strides Pharma Science
- 1520
- 127.5
- 9.16
- 1675.25
- 482.5
- 13968.76
- Shilpa Medicare
- 935.8
- 55.9
- 6.35
- 959.95
- 313.55
- 8122.93
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Marksans Pharma
- 42.46
- 6.7
- 19.36
- 14.03
- Granules India
- 32.91
- 4.15
- 18.62
- 11.82
- Glenmark Life Sciences
- 28.18
- 5.69
- 30.83
- 20.23
- Strides Pharma Science
- -
- 6.02
- -4.1
- -3.36
- Shilpa Medicare
- 273.35
- 4.22
- 4.6
- 7.03
Glenmark Life Sciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-Oct-24
- Quarterly Results
- 25-Jul-24
- Quarterly Results
- 25-Apr-24
- Audited Results
- 23-Jan-24
- Quarterly Results
- 20-Oct-23
- Quarterly Results
- 09-Oct-23
- Interim Dividend
- 21-Jul-23
- Quarterly Results
- 27-Apr-23
- Audited Results
- 16-Mar-23
- Interim Dividend
- 27-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 26-Sept-23
- 01-Sept-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 04-Oct-23
- 17-Oct-23
- 17-Oct-23
- 22.5
- 14-Mar-23
- 24-Mar-23
- 24-Mar-23
- 21
- 20-Apr-22
- -
- 15-Sept-22
- 10.5
- 10-Nov-21
- 23-Nov-21
- 22-Nov-21
- 10.5